Stability of the i.v. and oral formulations of etoposide in solution

[1]  M. Relling,et al.  Stability of etoposide solution for oral use. , 1992, American journal of hospital pharmacy.

[2]  M. Nahata,et al.  Stability of morphine sulfate in bacteriostatic 0.9% sodium chloride injection stored in glass vials at two temperatures. , 1992, American journal of hospital pharmacy.

[3]  A. C. Dubbelman,et al.  Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids. , 1991, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[4]  C. Stewart,et al.  Stability of cisplatin and etoposide in intravenous admixtures. , 1989, American journal of hospital pharmacy.

[5]  Jivn R. Chen,et al.  Preformulation Study of Etoposide: Identification of Physicochemical Characteristics Responsible for the Low and Erratic Oral Bioavailability of Etoposide , 1989, Pharmaceutical Research.

[6]  Nazeravich Dr,et al.  In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. , 1987 .

[7]  J. van der Greef,et al.  Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). , 1987, Cancer research.

[8]  S. Yalkowsky,et al.  A New Parenteral Emulsion for the Administration of Taxol , 1987, Pharmaceutical Research.

[9]  M. Slevin,et al.  Variable bioavailability following repeated oral doses of etoposide. , 1985, European journal of cancer & clinical oncology.

[10]  D. Crommelin,et al.  Absorption of Etoposide (VP-16-213) from the Small Intestine of the Rat. The Potential Role of Mucus as an Absorption Rate Limiting Barrier , 1985, Pharmaceutical Research.

[11]  A. E. Klein,et al.  Stability-indicating liquid chromatographic determination of etoposide and benzyl alcohol in injectable formulations. , 1985, Journal of pharmaceutical sciences.

[12]  M. D’Incalci,et al.  In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma. , 1982, European journal of cancer & clinical oncology.

[13]  A. Arnold.  Podophyllotoxin derivative VP 16-213 , 2004, Cancer Chemotherapy and Pharmacology.

[14]  L. Lenaz,et al.  Current development of podophyllotoxins , 2004, Cancer Chemotherapy and Pharmacology.

[15]  S. Joel,et al.  The effect of dose on the bioavailability of oral etoposide , 2004, Cancer Chemotherapy and Pharmacology.

[16]  J. Beijnen,et al.  Degradation kinetics of etoposide in aqueous solution , 1988 .

[17]  N. Kobrinsky,et al.  In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. , 1987, Cancer treatment reports.

[18]  M. Slevin,et al.  High-performance liquid chromatography of etoposide in plasma and urine. , 1985, Journal of chromatography.

[19]  D. Ayres,et al.  Determination of etoposide (VP16-213) and teniposide (VM-26) in serum by high-performance liquid chromatography with electrochemical detection. , 1984, Journal of pharmaceutical and biomedical analysis.